Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $61.4 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) rose 0.63% to $61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 0.63%. This contributed to the annual value of $61.4 million for FY2024, which is 22.67% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Shares Outstanding (Weighted Average) of $61.4 million as of FY2024, which was up 22.67% from $50.1 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) registered a high of $61.4 million during FY2024, and its lowest value of $42.5 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $50.1 million (2023), whereas its average is $53.3 million.
  • Data for Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 22.67% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) stood at $42.5 million in 2020, then rose by 9.32% to $46.5 million in 2021, then grew by 4.07% to $48.4 million in 2022, then increased by 3.48% to $50.1 million in 2023, then grew by 22.67% to $61.4 million in 2024.